News
LIVN
64.06
+0.25%
0.16
LivaNova (LIVN): Assessing Valuation After CMS Boosts Reimbursement for VNS Therapy Procedures
Simply Wall St · 15h ago
LivaNova To Present Eight Posters At AES Highlighting VNS Therapy's Seizure Reduction And Improved Outcomes In Drug-Resistant Epilepsy
Benzinga · 2d ago
LivaNova Highlights CORE-VNS Study Showing VNS Therapy Reduces Seizure Frequency and Healthcare Costs in Drug-Resistant Epilepsy
Reuters · 2d ago
LivaNova Names Lucile Blaise Global Head of Commercialization for Obstructive Sleep Apnea
Reuters · 3d ago
LIVANOVA APPOINTS LUCILE BLAISE AS GLOBAL HEAD OF COMMERCIALIZATION, OBSTRUCTIVE SLEEP APNEA
Reuters · 3d ago
Weekly Report: what happened at LIVN last week (1124-1128)?
Weekly Report · 4d ago
LivaNova (LIVN) Is Up 5.5% After Medicare Boosts VNS Therapy Reimbursement—Has the Bull Case Changed?
Simply Wall St · 4d ago
LivaNova CFO to Present Business Update at Piper Sandler Healthcare Conference
Reuters · 11/25 14:00
A Look at LivaNova's Valuation After CMS Lifts Medicare Payments for VNS Therapy
Simply Wall St · 11/25 00:19
LivaNova receives increased CMS reimbursement for VNS Therapy
TipRanks · 11/24 14:15
Weekly Report: what happened at LIVN last week (1117-1121)?
Weekly Report · 11/24 09:11
The Bull Case For LivaNova (LIVN) Could Change Following Q3 Beat and Ambitious 2030 Growth Targets
Simply Wall St · 11/23 20:10
LivaNova Director Makes a Noteworthy Stock Sale!
TipRanks · 11/20 02:13
LivaNova Director Brooke Story Reports Sale of Common Shares
Reuters · 11/19 20:57
Weekly Report: what happened at LIVN last week (1110-1114)?
Weekly Report · 11/17 09:11
Why LivaNova (LIVN) Is Up 11.4% After Raising 2025 Revenue Guidance Despite Lower Net Income
Simply Wall St · 11/14 00:39
LivaNova Is Maintained at Outperform by Mizuho
Dow Jones · 11/13 12:48
LivaNova Is Maintained at Outperform by Baird
Dow Jones · 11/13 12:46
Mizuho Maintains Outperform on LivaNova, Raises Price Target to $70
Benzinga · 11/13 12:38
Mizuho Securities Remains a Buy on LivaNova (LIVN)
TipRanks · 11/13 12:36
More
Webull provides a variety of real-time LIVN stock news. You can receive the latest news about Livanova Plc through multiple platforms. This information may help you make smarter investment decisions.
About LIVN
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.